Article
Hematology
Robert Puckrin, Neil Chua, Kelly Chin, Anthea Peters, Peter Duggan, Mona Shafey, Jan Storek, Kareem Jamani, Carolyn Owen, Douglas Stewart
Summary: ASCT demonstrates high rates of durable remission in relapsed FL, with long-term follow-up revealing that more than 50% of transplanted patients may be functionally cured of their lymphoma. The optimal timing to consider ASCT is at first or second relapse, regardless of POD24 status.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Lakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, Reid D. Landes, Mathew Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel A. Mitma, Clyde Bailey, Kerri M. Hill, Sharmilan Thanendrarajan, Monica Graziutti, Meera Mohan, Maurizio Zangari, Frits van Rhee, Guido Tricot, Carolina Schinke
Summary: Multiple Myeloma (MM) is a common cancer of the bone marrow that remains incurable despite advancements in therapy. While Daratumumab has improved survival rates, heavily pretreated patients who progress on this treatment have poor clinical outcomes. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be a viable treatment option for selected patients who are refractory to Daratumumab.
Review
Oncology
Xinsheng Liu, Yaxin Zheng, Hongtao Li, Meiyi Wang, M. James You, Chen Tian
Summary: The effect of autologous hematopoietic stem cell transplantation (auto-HSCT) versus conventional chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT) on the survival of patients with advanced follicular lymphoma (FL) is uncertain. This study included 13 studies and found that auto-HSCT improved overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) compared with conventional chemotherapy. In addition, auto-HSCT resulted in longer OS and lower non-relapse mortality (NRM) compared with allo-HSCT.
Article
Oncology
Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, Natalia Becker, Christina Habermehl, Thomas Hielscher, Marc-Steffen Raab, Jens Hillengass, Sandra Sauer, Carsten Mueller-Tidow, Steffen Luntz, Anna Jauch, Dirk Hose, Anja Seckinger, Peter Brossart, Martin Goerner, Stefan Klein, Martin Schmidt-Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Hans Martin, Hans W. Lindemann, Christoph Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel
Summary: The efficacy of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) has not been clearly defined in the era of continuous novel agent treatment, however, patients who received this treatment may have benefited.
Article
Oncology
Issa F. Khouri, Denai R. Milton, Alison M. Gulbis, Elias J. Jabbour, Loretta Nastoupil, Celina Ledesma, Paolo Anderlini, Qaiser Bashir, May Daher, Jin S. Im, Swaminathan P. Iyer, David Marin, Rohtesh S. Mehta, Amanda L. Olson, Uday R. Popat, Muzaffar Qazilbash, Neeraj Saini, Felipe Samaniego, Gabriela Rondon, L. Jeffrey Medeiros, Richard E. Champlin
Summary: In patients with relapsed follicular lymphoma, receiving alloSCT has been shown to confer better overall survival and progression-free survival compared to autoSCT.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Marc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Mueller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass, Nicola Giesen
Summary: Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) following re-induction treatment with carfilzomib/lenalidomide/dexamethasone (KRd) led to deep remissions and prolonged progression-free survival (PFS) in patients with relapsed and/or refractory multiple myeloma (RRMM). Maintenance treatment post salvage HDCT/ASCT further enhanced PFS, making this a safe and effective strategy for RRMM patients.
Article
Oncology
Huixing Zhou, Yuan Jian, Juan Du, Junru Liu, Zhiyao Zhang, Guangzhong Yang, Guorong Wang, Ying Tian, Yanchen Li, Yin Wu, Wenming Chen, Weijun Fu, Juan Li, Wen Gao
Summary: This study aimed to establish a predictive nomogram for early relapse after autologous stem cell transplantation in multiple myeloma patients. The nomogram showed higher accuracy compared to other staging systems, suggesting its potential for modifying post-ASCT strategies for high-risk patients.
Article
Oncology
Zhenghua Huang, Zhen Li, Juan Wang, Ruirui Gui, Yingling Zu, Fengkuan Yu, Quande Lin, Huifang Zhao, Yanli Zhang, Baijun Fang, Yanyan Liu, Keshu Zhou, Yufu Li, Yuewen Fu, Zhihua Yao, Yongping Song, Jian Zhou
Summary: The efficacy of autologous hematopoietic stem cell transplantation (ASCT) in peripheral T-cell lymphoma (PTCL) remains controversial. This study suggests that ASCT benefits patients with complete remission (CR), while post-transplant maintenance therapy improves outcomes for patients with partial remission (PR).
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Fabio Guolo, Paola Minetto, Silvia Pesce, Filippo Ballerini, Marino Clavio, Michele Cea, Michela Frello, Matteo Garibotto, Marco Greppi, Matteo Bozzo, Maurizio Miglino, Monica Passannante, Riccardo Marcolin, Elisabetta Tedone, Nicoletta Colombo, Rosa Mangerini, Alessandra Bo, Maria Rosaria Ruzzenenti, Paolo Carlier, Alberto Serio, Silvia Luchetti, Alida Dominietto, Riccardo Varaldo, Simona Candiani, Vanessa Agostini, Jean Louis Ravetti, Genny Del Zotto, Emanuela Marcenaro, Roberto Massimo Lemoli
Summary: This study aimed to investigate a novel therapeutic approach for Hodgkin Lymphoma patients, using a combination of autologous lymphocytes and immune checkpoint inhibitors, which proved to have anti-tumor efficacy and accelerated the development of specific immune cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Editorial Material
Hematology
Peter W. M. Johnson
Summary: The study shows that treating relapsed or refractory HL with PD-1 antibody nivolumab has a high response rate, making it an attractive option for second-line therapy.
Article
Hematology
Mizuki Watanabe, Junya Kanda, Takahiro Fukuda, Naoyuki Uchida, Kazuhiro Ikegame, Keisuke Kataoka, Hikaru Kobayashi, Takahide Ara, Jun Ishikawa, Ken-ichi Matsuoka, Yasuhiro Sugio, Hideyuki Nakazawa, Takashi Ikeda, Yoshiko Atsuta, Eisei Kondo, Ritsuro Suzuki
Summary: The impact of acute and chronic graft versus host disease (aGVHD, cGVHD) on lymphoma progression and transplant outcomes was studied in 2204 Japanese patients with non-Hodgkin lymphomas. While aGVHD/cGVHD had no statistical impact on lymphoma progression in the overall cohort, their impact was significant in certain groups. Limited cGVHD was associated with superior survival, while severe GVHDs showed negative impacts on them.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biophysics
Toby A. Eyre, Sophie Caillard, Herve Finel, Ariane Boumendil, Jaimal Kothari, Heiner Zimmermann, Ralf Ulrich Trappe, Virginie De Wilde, Eleni Tholouli, Edward Kanfer, Angus Broom, Gandhi Damaj, Mario Bargetzi, Tomas Kozak, Inken Hilgendorf, Charles Crawley, Tessa Kerre, Marek Trneny, Emmanuel Bachy, Stephen Robinson, Silvia Montoto
Summary: This retrospective analysis of 21 patients who underwent autoSCT for PTLD post solid organ transplant found that although autoSCT is feasible and potentially effective, it is associated with a high non-relapse mortality primarily driven by infectious toxicity. A multidisciplinary approach, expert microbiological input, and stringent patient selection are necessary to optimize outcomes.
BONE MARROW TRANSPLANTATION
(2021)
Article
Oncology
Ali Bazarbachi, Ariane Boumendil, Herve Finel, Irma Khvedelidze, Joanna Romejko-Jarosinska, Alina Tanase, Saad Akhtar, Tarek Ben Othman, Mohammad Ma'koseh, Boris Afanasyev, Jean Cheikh, Javier Briones, Zafer Gulbas, Rose-Marie Hamladji, Tugrul Elverdi, Didier Blaise, Carmen Martinez, Eleonora Alma, Kazimierz Halaburda, Aida Botelho Sousa, Bertram Glass, Steven Robinson, Silvia Montoto, Anna Sureda
Summary: The outcome after relapse following autologous-stem-cell-transplantation (auto-SCT) has significantly improved in recent years, especially in the case of early relapse. Younger age, good performance status, smaller tumor burden, absence of extranodal disease, and absence of B symptoms were associated with better prognosis.
Article
Oncology
Alicia Bao, Qiuhong Zhao, Ruchi Kudalkar, Jose Rodriguez, Nidhi Sharma, Naresh Bumma, Srinivas S. Devarakonda, Abdullah M. Khan, Elvira Umyarova, Ashley E. Rosko, Don Benson, Francesca Cottini
Summary: In patients with multiple myeloma undergoing autologous stem cell transplant, a gap between induction therapy and transplant allows for stem cell mobilization. However, some patients experience disease progression during this interval, which can impact response to transplant.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Ana Muntanola, Pablo Mozas, Santiago Mercadal, Maria Huguet, Sabela Bobillo, Mariana Bastos-Oreiro, Ana Jimenez-Ubieto, Jordina Rovira, Andrea Rivero, Carles Tolosa, Luis Luizaga, Sonia Gonzalez de Villambrosia, Silvana Novelli, Dolores Caballero, Antonio Salar, Sara Alonso-Alvarez, Laura Magnano, Norma C. Gutierrez, Juan-Manuel Sancho, Armando Lopez-Guillermo
Summary: Although follicular lymphoma patients who relapse within 24 months after first-line treatment have a poor prognosis, some cases show notable survival after the first relapse. Prognostic factors at progression include age, LDH levels, Hb levels, disease stage, FLIPI risk score, histological transformation, and response to salvage therapy. Patients with low/intermediate FLIPI and no histological transformation at first relapse tend to have better outcomes.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Clinical Neurology
David Wasilewski, Martin Janz, Arend Koch, Andreas Rosenwald, Ulrich Keller, Peter Vajkoczy, Katharina Faust, Ioannis Anagnostopoulos, Josefine Radke
ACTA NEUROLOGICA BELGICA
(2023)
Article
Education & Educational Research
Jessica Levy, Martin Brunner, Ulrich Keller, Antoine Fischbach
Summary: There is no consensus on the covariates that should be used in addition to prior achievement when evaluating a school's effectiveness using value-added (VA) scores. This study examined the sensitivity of evaluations of math and language achievement to different covariate selections in the applied VA model. The findings showed that prior math and language achievement, along with sociodemographic and sociocultural background characteristics, significantly improved the explained variance and consistency of school VA scores. Therefore, caution should be exercised when using VA models, and VA scores should be used for informative purposes rather than as the sole basis for accountability decisions.
EDUCATIONAL ASSESSMENT EVALUATION AND ACCOUNTABILITY
(2023)
Article
Hematology
Guus J. J. E. Heynen, Francis Baumgartner, Michael Heider, Upayan Patra, Maximilian Holz, Jan Braune, Melanie Kaiser, Isabell Schaeffer, Stefanos A. Bamopoulos, Evelyn Ramberger, Arunima Murgai, Yuen Lam Dora Ng, Uta Margareta Demel, Dominik Laue, Sven Liebig, Josefine Krueger, Martin Janz, Axel Nogai, Markus Schick, Philipp Mertins, Stefan Mueller, Florian Bassermann, Jan Kroenke, Ulrich Keller, Matthias Wirth
Summary: Proteasome inhibition is a highly effective treatment for multiple myeloma, but patients often develop resistance to proteasome inhibitors. Increased SUMOylation has been found in relapsed/refractory MM, and high expression of the SUMO E1-activating enzyme is associated with poor survival. Combination therapy with the SUMO E1-activating enzyme inhibitor and proteasome inhibitor showed synergy in MM cell lines and primary MM cells. Activated SUMOylation can be a therapeutic target for MM and combined SUMO/proteasome inhibition may be a potential strategy for treating proteasome inhibitor-resistant MM.
Article
Hematology
Uta M. Demel, Matthias Wirth, Schayan Yousefian, Le Zhang, Konstandina Isaakidis, Judith Doenig, Marlitt Boger, Nikita Singh, Hazal Koese, Simon Haas, Stefan Mueller, Markus Schick, Ulrich Keller
Summary: Aberrant activity of the SUMOylation pathway has been associated with MYC overexpression and poor prognosis in aggressive B-cell lymphoma (BCL) and other malignancies. Recently developed small-molecule inhibitors of SUMOylation (SUMOi) target the heterodimeric E1 SUMO activation complex (SAE1/UBA2). In vitro and in a preclinical murine in vivo model, activated MYC signaling was found to be an actionable molecular vulnerability. SUMOi not only directly affected MYC-driven lymphoma cells, but also resulted in substantial remodeling of various subsets of the innate and specific immunity in vivo.
Article
Cardiac & Cardiovascular Systems
Ruben Evertz, Katharina Goedde, Christine Diehl, Miroslava Valentova, Tania Garfias-Veitl, Friederike Braulke, Gerald G. Wulf, Tobias R. Overbeck, Annalen Bleckmann, Alexander O. Koenig, Pia Weinlaender, Sophia Potthoff, Sara Hadzibegovic, Alessia Lena, Ulrich Keller, Ulf Landmesser, Andreas Schuster, Markus S. Anker, Gerd Hasenfuss, Stephan von Haehling
Summary: This study aimed to identify the major determinants of quality of life (QoL) in patients undergoing cancer treatment and treatment-naive patients. The study found that age, resting heart rate, hand grip strength, cachexia, and dyspnoea were independently predictive of reduced QoL.
Article
Biochemistry & Molecular Biology
Paul Schossig, Ebru Coskun, Ruza Arsenic, David Horst, Jalid Sehouli, Eva Bergmann, Nadine Andresen, Christian Sigler, Antonia Busse, Ulrich Keller, Sebastian Ochsenreither
Summary: This study identified and prioritized suitable tumor-associated antigens for adoptive T cell-receptor therapy in epithelial ovarian cancer. KIF20A, CT45, and LY6K were identified as the most promising targets based on their high expression and peptide presence in ligandome analysis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Olivier Hermine, Linmiao Jiang, Jan Walewski, Andre Bosly, Catherine Thieblemont, Michal Szymczyk, Christiane Pott, Gilles Salles, Pierre Feugier, Kai Hubel, Corinne Haioun, Rene Olivier Casasnovas, Christian Schmidt, Kamal Bouabdallah, Vincent Ribrag, Lothar Kanz, Jan Durig, Bernd Metzner, David Sibon, Morgane Cheminant, Barbara Burroni, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Martin Dreyling
Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies for which the primary end point has already been reported. This study confirms the previously observed substantially prolonged time to treatment failure and shows an improvement in overall survival for patients with Mantle Cell Lymphoma. Some patients with MCL may be cured.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Endocrinology & Metabolism
Viktoria Florentine Koehler, Thomas Knoesel, Sandra Elisabeth Hasmann, Clemens Scherer, Johannes C. Hellmuth, Maximilian Muenchhoff, Stefan Micheal Munker, Eva Hoster, Roland Ladurner, Christine Spitzweg
Summary: SARS-CoV-2 infection can lead to endocrine disorders such as thyroiditis and pituitary dysfunction, and ACE2 receptor is present in thyroid tissue. Abnormal TFTs are associated with the severity of the disease in COVID-19 patients.
Article
Cardiac & Cardiovascular Systems
Alessia Lena, Ursula Wilkenshoff, Sara Hadzibegovic, Jan Porthun, Lukas Roesnick, Ann-Kathrin Froehlich, Tanja Zeller, Mahir Karakas, Ulrich Keller, Johann Ahn, Lars Bullinger, Hanno Riess, Stuart D. Rosen, Alexander R. Lyon, Thomas F. Luescher, Matthias Totzeck, Tienush Rassaf, Daniel Burkhoff, Mandeep R. Mehra, Jeroen J. Bax, Javed Butler, Frank Edelmann, Wilhelm Haverkamp, Stefan D. Anker, Milton Packer, Andrew J. S. Coats, Stephan von Haehling, Ulf Landmesser, Markus S. Anker
Summary: This study found that cancer patients have cardiac wasting and decreased heart function. Low left ventricular mass is associated with poor functional status and increased all-cause mortality in cancer patients.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Geriatrics & Gerontology
Markus S. Anker, Alessia Lena, Eric J. Roeland, Jan Porthun, Sebastian Schmitz, Sara Hadzibegovic, Philipp Sikorski, Ursula Wilkenshoff, Ann-Kathrin Froehlich, Luisa Valentina Ramer, Matthias Rose, Jan Eucker, Tienush Rassaf, Matthias Totzeck, Lorenz H. Lehmann, Stephan von Haehling, Andrew J. S. Coats, Tim Friede, Javed Butler, Stefan D. Anker, Hanno Riess, Ulf Landmesser, Lars Bullinger, Ulrich Keller, Johann Ahn
Summary: The patient-reported ability to walk 4 m and wash oneself is an independent predictor of survival and associated with decreased functional status in pre-terminal cancer patients.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2023)
Article
Oncology
Viktoria Ingwersen, Joerg Hofmann, Marion Muche, Philipp Le Coutre, Thomas Schneider, Corinna Leng, Thomas Burmeister, Georg Maschmeyer, Ulrich Keller, Stefan Schwartz
Summary: This study retrospectively analyzed 22 immunocompromised patients and found that hepatitis E virus (HEV) could cause chronic infections in these patients. Some patients achieved viral clearance with ribavirin therapy, but others still could not clear the virus and may develop liver failure.
ONCOLOGY RESEARCH AND TREATMENT
(2023)
Article
Oncology
Sabrina Kalmbach, Michael Grau, Myroslav Zapukhlyak, Ellen Leich, Vindi Jurinovic, Eva M. Hoster, Annette S. Staiger, Katrin Kurz, Oliver Weigert, Erik Gaitzsch, Verena Passerini, Marianne Engelhard, Klaus Herfarth, Klaus Beiske, Francesca Micci, Peter Moeller, Heinz-Wolfram C. Bernd, Alfred Feller, Wolfram Klapper, Harald Stein, Martin-Leo Hansmann, Sylvia Hartmann, Martin Dreyling, Harald Holte, Georg Lenz, Andreas Rosenwald, German Ott, Heike Horn, German Lymphoma Alliance GLA
Summary: Comprehensive analysis of localized follicular lymphoma (lFL) and systemic follicular lymphoma (sFL) revealed overlapping genetic and chromosomal abnormalities. However, significant differences were found in the frequency of chromosomal alterations, specifically in 18q gains. Rare gains in 18q21 were associated with inferior progression-free survival in lFL. ARID1A mutations were more frequently detected in sFL compared to lFL. This study provides novel insights and identifies 18q21 gains as a prognostic marker in lFL.
Article
Oncology
Gabriel Scheubeck, Linmiao Jiang, Olivier Hermine, Hanneke C. Kluin-Nelemans, Christian Schmidt, Michael Unterhalt, Andreas Rosenwald, Wolfram Klapper, Andrea Evangelista, Marco Ladetto, Mats Jerkeman, Simone Ferrero, Martin Dreyling, Eva Hoster
Summary: The current treatment allocation for patients with Mantle Cell Lymphoma (MCL) relies on age and medical fitness. However, a combination of clinical factors (MIPI) and the Ki-67 index have shown limited predictive value. This study aimed to identify a high-risk group based on the combination of MIPI, Ki-67, and p53 expression/TP53 alteration. The findings suggest that patients in this high-risk group have significantly worse outcomes compared to low-risk patients and may require alternative treatment strategies.
Letter
Hematology
Viktoria Blumenberg, Galina Busch, Stephan Baumann, Regina Jitschin, Gloria Iacoboni, Laura Gallur, Josu Iraola-Truchuelo, Eva Hoster, Michael Winkelmann, Konstantin Hellwig, Christian Schmidt, Lisa Froelich, Benjamin Tast, Friederike Hildebrand, Kai Rejeski, Franziska Dekorsy, Christian Schmidkonz, Tobias Baeuerle, Wolfgang G. Kunz, Dimitrios Mougiakakos, Fabian Mueller, Michael von Bergwelt-Baildon, Pere Barba, Veit L. Buecklein, Andreas Mackensen, Simon Voelki, Marion Subklewe
Article
Hematology
Veit Buecklein, Ariel Perez, Kai Rejeski, Gloria Iacoboni, Vindi Jurinovic, Udo Holtick, Olaf Penack, Soraya Kharboutli, Viktoria Blumenberg, Josephine Ackermann, Lisa Froelich, Grace Johnson, Kedar Patel, Brian Arciola, Rahul Mhaskar, Anthony Wood, Christian Schmidt, Omar Albanyan, Philipp Goedel, Eva Hoster, Lars Bullinger, Andreas Mackensen, Frederick Locke, Michael von Bergwelt, Pere Barba, Marion Subklewe, Michael D. Jain
Summary: Real-world evidence shows that patients receiving CD19 chimeric antigen receptor (CAR) T-cell therapy in Europe and with tisagenlecleucel have inferior survival outcomes. The reasons for these discrepancies are poorly understood.